Literature DB >> 26847635

Surgical treatment of mucoepidermoid carcinoma of the lung: 20 years' experience.

Takayoshi Yamamoto1, Takahiro Nakajima2, Hidemi Suzuki1, Tetsuzo Tagawa1, Takekazu Iwata1, Teruaki Mizobuchi1, Shigetoshi Yoshida1, Yukio Nakatani3, Ichiro Yoshino1.   

Abstract

BACKGROUND: Pulmonary mucoepidermoid carcinoma is a rare salivary gland-type neoplasm. We aimed to elucidate the optimal management of this rare condition by reviewing the treatment outcomes of patients at our institution with mucoepidermoid carcinoma of the lung.
METHODS: We performed a retrospective review of all patients with pulmonary mucoepidermoid carcinoma who underwent surgical treatment between January 1993 and December 2012. We reviewed the patients' clinical characteristics and the therapeutic interventions undertaken.
RESULTS: Nine patients were evaluated in this study, 7 of whom were female. The median age of all patients was 54 years (range 10-72 years). Six patients had tumors of a low histologic grade, and the other 3 had high-grade malignancies. Prior to surgery, 2 patients required endobronchial intervention for obstructive pneumonia. Eight patients underwent lobectomy, and one had a bilobectomy. Two patients required bronchoplasty, and one required resection of the left atrium for complete resection of the primary neoplasm. Two patients with advanced disease and high-grade tumors died due to cancer progression. The overall 5-year survival rate was 72.9%. One patient with a high-grade malignancy demonstrated exon 21 mutation of the epidermal growth factor receptor gene.
CONCLUSIONS: Complete surgical resection is important for long-term survival in patients with pulmonary mucoepidermoid carcinoma. The techniques of bronchoplasty and extended resection may contribute to better surgical management of this disease. Endobronchial interventions may be considered for the management of obstructive pneumonia prior to surgery.
© The Author(s) 2016.

Entities:  

Keywords:  Bronchial neoplasms; Carcinoma; Lung neoplasms; Pneumonectomy; Receptor; Survival rate; epidermal growth factor; mucoepidermoid

Mesh:

Substances:

Year:  2016        PMID: 26847635     DOI: 10.1177/0218492316630494

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  7 in total

1.  [Mucoepidermoid Carcinoma of the Lung: Report of 29 Cases].

Authors:  Jingjing Hou; Huijuan Wang; Guowei Zhang; Yanyang Huang; Zhiyong Ma
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-03-20

2.  Predictive CT features for the diagnosis of primary pulmonary mucoepidermoid carcinoma: comparison with squamous cell carcinomas and adenocarcinomas.

Authors:  Xiaohua Ban; Xinping Shen; Huijun Hu; Rong Zhang; Chuanmiao Xie; Xiaohui Duan; Cuiping Zhou
Journal:  Cancer Imaging       Date:  2021-01-06       Impact factor: 3.909

3.  Metastatic mucoepidermoid carcinoma to the pleura: a case report.

Authors:  Simran Mashiana; Ernesto Martinez Duarte
Journal:  J Med Case Rep       Date:  2022-02-16

4.  Surgical treatment of primary tracheobronchial tumors: 16-year experience in a single center.

Authors:  Yujian Liu; Kaifu Zheng; Qiang Lu; Jian Wang; Yunfeng Ni; Xiaolong Yan; Lei Wang; Xiyang Tang; Jing Huang; Xiaofei Li; Jinbo Zhao
Journal:  J Thorac Dis       Date:  2022-02       Impact factor: 2.895

5.  Pulmonary mucoepidermoid carcinoma: A clinicopathological study of 45 patients.

Authors:  Wang Shen; Tao Yang; Yaguang Fan; Xuebing Li; Cheng Ai; Xinyun Wang; Dan Wang; Xuexia Zhou
Journal:  Thorac Cancer       Date:  2022-06-23       Impact factor: 3.223

6.  Clinicopathological characteristics and molecular analysis of primary pulmonary mucoepidermoid carcinoma: Case report and literature review.

Authors:  Xuanguang Li; Zhibin Guo; Jinghao Liu; Sen Wei; Dian Ren; Gang Chen; Song Xu; Jun Chen
Journal:  Thorac Cancer       Date:  2017-11-28       Impact factor: 3.500

7.  A Comparative Study of Primary Adenoid Cystic and Mucoepidermoid Carcinoma of Lung.

Authors:  Vivek Kumar; Parita Soni; Mohit Garg; Abhishek Goyal; Trishala Meghal; Stephan Kamholz; Abhinav Binod Chandra
Journal:  Front Oncol       Date:  2018-05-15       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.